HALOZYME THERAPEUTICS INC

NASDAQ: HALO (Halozyme Therapeutics, Inc.)

最近更新时间: 3天之前, 3:06PM

56.07

1.34 (2.45%)

前收盘价格 54.73
收盘价格 54.75
成交量 2,148,569
平均成交量 (3个月) 2,179,862
市值 6,909,001,216
市盈率 (P/E TTM) 14.91
预期市盈率 (P/E Forward) 11.22
价格/销量 (P/S) 6.48
股市价格/股市净资产 (P/B) 13.94
52周波幅
42.01 (-25%) — 70.51 (25%)
利润日期 4 Aug 2025 - 8 Aug 2025
营业毛利率 44.76%
营业利益率 (TTM) 53.44%
稀释每股收益 (EPS TTM) 3.76
季度收入增长率 (YOY) 35.20%
季度盈利增长率 (YOY) 53.70%
总债务/股东权益 (D/E MRQ) 318.67%
流动比率 (MRQ) 8.39
营业现金流 (OCF TTM) 503.86 M
杠杆自由现金流 (LFCF TTM) 402.43 M
资产报酬率 (ROA TTM) 18.50%
股东权益报酬率 (ROE TTM) 147.06%

市场趋势

短期 中期
行业 Biotechnology (US) 看跌 看跌
Biotechnology (全球的) 看跌 看跌
股票 Halozyme Therapeutics, Inc. 看跌 看涨

AIStockmoo 评分

0.5
分析师共识 -0.5
内部交易活动 NA
价格波动 2.0
技术平均移动指标 2.5
技术振荡指标 -2.0
平均 0.50

相关股票

股票 市值 DY P/E(TTM) P/B
HALO 7 B - 14.91 13.94
EXEL 12 B - 19.57 5.57
CORT 8 B - 67.44 12.02
MDGL 6 B - - 9.36
TGTX 6 B - 140.44 26.86
NUVL 6 B - - 5.09

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.

部门 Healthcare
行业 Biotechnology
投资方式 Small Growth
内部持股比例 1.17%
机构持股比例 102.21%

所有权

姓名 日期 持有股份
Snyder Capital Management L P 31 Mar 2025 3,674,302
Congress Asset Management Co 31 Mar 2025 2,132,707
52周波幅
42.01 (-25%) — 70.51 (25%)
目标价格波幅
47.00 (-16%) — 72.00 (28%)
72.00 (HC Wainwright & Co., 28.41%) 购买
62.00 (10.58%)
47.00 (Leerink Partners, -16.18%) 卖出
平均值 60.80 (8.44%)
总计 1 购买, 3 保留, 1 卖出
平均价格@调整类型 56.06
公司 日期 目标价格 调整类型 价格@调整类型
HC Wainwright & Co. 29 May 2025 72.00 (28.41%) 购买 54.73
25 Apr 2025 72.00 (28.41%) 购买 60.49
Morgan Stanley 14 May 2025 62.00 (10.58%) 保留 47.91
Leerink Partners 13 May 2025 47.00 (-16.18%) 卖出 50.23
Wells Fargo 07 May 2025 65.00 (15.93%) 保留 70.14
JP Morgan 21 Apr 2025 58.00 (3.44%) 保留 57.29

该时间范围内无数据。

日期 类型 细节
28 May 2025 公告 Halozyme Announces Bristol Myers Squibb Received European Commission Approval for Subcutaneous Opdivo® (nivolumab) Co-Formulated with ENHANZE® Across Multiple Solid Tumor Indications
28 May 2025 公告 Halozyme to Participate at Upcoming Investor Conferences
06 May 2025 公告 HALOZYME RAISES 2025 FINANCIAL GUIDANCE RANGES AND REPORTS STRONG FIRST QUARTER 2025 RESULTS
05 May 2025 公告 Halozyme to Participate in the BofA Securities 2025 Healthcare Conference
28 Apr 2025 公告 Halozyme to Report First Quarter 2025 Financial and Operating Results
28 Apr 2025 公告 Halozyme Announces argenx Received Positive CHMP Opinion for VYVGART® (efgartigimod alfa) Subcutaneous Injection with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
24 Apr 2025 公告 Halozyme Sues Merck for Patent Infringement over Subcutaneous Keytruda Formulation
10 Apr 2025 公告 Halozyme Announces FDA Approval of argenx's VYVGART® Hytrulo Prefilled Syringe Co-Formulated with ENHANZE® for Self-Injection for Generalized Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy
09 Apr 2025 公告 European Commission Approved Subcutaneous DARZALEX® (daratumumab)-based Quadruplet Regimen for the Treatment of Patients with Newly Diagnosed Multiple Myeloma, Regardless of Transplant Eligibility
07 Apr 2025 公告 European Commission Approves Subcutaneous RYBREVANT® (amivantamab) Co-Formulated with ENHANZE® for the Treatment of Patients with Advanced EGFR-Mutated Non-Small Cell Lung Cancer
31 Mar 2025 公告 Halozyme Announces Bristol Myers Squibb Received Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) with ENHANZE® Across Multiple Solid Tumor Indications
显示更多

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票